Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity
Michael Linecker, Bergthor Björnsson, Gregor A Stavrou, Karl J Oldhafer, Georg Lurje, Ulf Neumann, René Adam, Francois-René Pruvot, Stefan A Topp, Jun Li, Ivan Capobianco, Silvio Nadalin, Marcel Autran Machado, Sergey Voskanyan, Deniz Balci, Roberto Hernandez-Alejandro, Fernando A Alvarez, Eduardo De Santibañes, Ricardo Robles-Campos, Massimo Malagó, Michelle L de Oliveira, Mickael Lesurtel, Pierre-Alain Clavien, Henrik Petrowsky, Michael Linecker, Bergthor Björnsson, Gregor A Stavrou, Karl J Oldhafer, Georg Lurje, Ulf Neumann, René Adam, Francois-René Pruvot, Stefan A Topp, Jun Li, Ivan Capobianco, Silvio Nadalin, Marcel Autran Machado, Sergey Voskanyan, Deniz Balci, Roberto Hernandez-Alejandro, Fernando A Alvarez, Eduardo De Santibañes, Ricardo Robles-Campos, Massimo Malagó, Michelle L de Oliveira, Mickael Lesurtel, Pierre-Alain Clavien, Henrik Petrowsky
Abstract
Objective: To longitudinally assess whether risk adjustment in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) occurred over time and is associated with postoperative outcome.
Background: ALPPS is a novel 2-stage hepatectomy enabling resection of extensive hepatic tumors. ALPPS has been criticized for its high mortality, which is reported beyond accepted standards in liver surgery. Therefore, adjustments in patient selection and technique have been performed but have not yet been studied over time in relation to outcome.
Methods: ALPPS centers of the International ALPPS Registry having performed ≥10 cases over a period of ≥3 years were assessed for 90-day mortality and major interstage complications (≥3b) of the longitudinal study period from 2009 to 2015. The predicted prestage 1 and 2 mortality risks were calculated for each patient. In addition, questionnaires were sent to all centers exploring center-specific risk adjustment strategies.
Results: Among 437 patients from 16 centers, a shift in indications toward colorectal liver metastases from 53% to 77% and a reverse trend in biliary tumors from 24% to 9% were observed. Over time, 90-day mortality decreased from initially 17% to 4% in 2015 (P = 0.002). Similarly, major interstage complications decreased from 10% to 3% (P = 0.011). The reduction of 90-day mortality was independently associated with a risk adjustment in patient selection (P < 0.001; OR: 1.62; 95% CI: 1.36-1.93) and using less invasive techniques in stage-1 surgery (P = 0.019; OR: 0.39; 95% CI: 0.18-0.86). A survey indicated risk adjustment of patient selection in all centers and ALPPS technique in the majority (80%) of centers.
Conclusions: Risk adjustment of patient selection and technique in ALPPS resulted in a continuous drop of early mortality and major postoperative morbidity, which has meanwhile reached standard outcome measures accepted for major liver surgery.
Source: PubMed
Prochains essais cliniques
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied...Pas encore de recrutementMotricité | En bonne santé | Fonction exécutive
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCPas encore de recrutementCarcinome épidermoïde anal
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaPas encore de recrutementLa polyarthrite rhumatoïde | Maladie articulaire dégénérative du genouItalie
-
University of Wisconsin, MadisonAlkermes, Inc.Pas encore de recrutement
-
Virginia Commonwealth UniversityPas encore de recrutement
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount...Pas encore de recrutementKétamine | IRMf | Dépression - Trouble dépressif majeur | SMTr | Dépression résistante au traitement (TRD)États-Unis
-
Weill Medical College of Cornell UniversityBD2 LLCPas encore de recrutementIRMf | Trouble bipolaire (TB) | SMTr | Dépression bipolaire 1États-Unis
-
Xentria, Inc.Pas encore de recrutement
-
Yale UniversityNational Institute of Mental Health (NIMH)Pas encore de recrutement
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRecrutementPhéochromocytome | Phéochromocytome/Paragangliome | Phéochromocytome métastatique | Phéochromocytome malin | Phéochromocytome et paragangliome (PPGL)Royaume-Uni
-
Carl Zeiss Meditec-Dublin CoCeRecrutementMembrane épirétinienne | Maladie de la rétine | Dégénérescence maculaire liée à l'âge sec | Anomalie vitréorétinienne | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal...États-Unis
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityRecrutementCLDN18.2 Tumeurs solides positivesChine